Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 13, 2024 05:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion...
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Recursion Pharmaceuticals
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will...
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
May 02, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion to Participate in Upcoming Investor Conferences
May 01, 2024 08:01 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program
April 30, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Altitude Lab and the Small Business Administration (SBA) are pleased to announce Horizon, a commercialization program to connect startups to...
Recursion to Participate in Upcoming Investor Conference
April 02, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Publishes Annual Environmental, Social and Governance Report
March 26, 2024 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 26, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced...
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
March 01, 2024 14:58 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, hosted its second annual Rare...
Recursion to Participate in Upcoming Investor Conferences
March 01, 2024 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 27, 2024 16:05 ET
|
Recursion Pharmaceuticals
Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the...